Evidence map›Paper›PMID 41870149›Full record

ArticleAntimicrobial agents and chemotherapy2026

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.

Sara M Karaba, Dariusz A Hareza, Jose M Munita, Jose R W Martinez, Yehudit Bergman, Armani M Hawes, Zackery P Bulman, Sara E Cosgrove, Patricia J Simner, Pranita D Tamma

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara M KarabaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8452-5549
Dariusz A HarezaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jose M MunitaInstituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.ORCID 0000-0002-7870-1056
Jose R W MartinezInstituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.ORCID 0000-0002-9733-1118
Yehudit BergmanDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Armani M HawesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Zackery P BulmanDepartment of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.ORCID 0000-0002-5396-911X
Sara E CosgroveDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Patricia J SimnerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6134-151X
Pranita D TammaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-4143-6324

Funding

NIH HHS K24-AI185302NIH HHS R21-AI173475Prevention Epicenters Program of the Centers for Disease Control and Prevention 5 U54CK000617-02-00Prevention Epicenters Program of the Centers for Disease Control and Prevention 6 U54CK000617-01-02
6 · The paper itself

Abstract

Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam. Emergence of resistance was higher in the ceftazidime-avibactam group (12% vs 0%); putative resistance mechanisms included porin mutations (

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesBoronic AcidsCeftazidimeEnterobacteriaceae InfectionsMeropenemThienamycinsBacterial ProteinsDrug CombinationsHeterocyclic Compounds, 1-RingHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsPorinsThird Generation CephalosporinsAmpC beta-lactamasesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesBoronic AcidsCeftazidimeDrug CombinationsHeterocyclic Compounds, 1-RingMeropenemmeropenem and vaborbactamPorinsThienamycinsThird Generation Cephalosporinsvaborbactamantimicrobial resistancecarbapenemasesCRE

Identifiers

PMID41870149
PMCPMC13148039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.